You are here

gene editing

[video+transcript] Gene-Editing Stocks Took Stutter Steps Forward in 2018

[video+transcript] Gene-Editing Stocks Took Stutter Steps Forward in 2018

Motley Fool

Vertex Pharmaceuticals

CRISPR Therapeutics

Sangamo BioSciences

Flag link:

Making CRISPR-Cas9 gene editing safer with artificial intelligence

Making CRISPR-Cas9 gene editing safer with artificial intelligence

Fierce Biotech

artificial intelligence

Flag link:

Sparse public data on CRISPR’d embryos leave many questions unanswered

Sparse public data on CRISPR’d embryos leave many questions unanswered

Stat

Flag link:

The Amazing Ways Artificial Intelligence Is Transforming Genomics and Gene Editing

The Amazing Ways Artificial Intelligence Is Transforming Genomics and Gene Editing

Forbes

artificial intelligence

Flag link:

CRISPR, MaxCyte expand partnership into immuno-oncology

CRISPR, MaxCyte expand partnership into immuno-oncology

Pharmaceutical Business Review

CRISPR Therapeutics

immuno-oncology

Flag link:

FDA preps for a new and flexible approach to genome editing in animals

FDA preps for a new and flexible approach to genome editing in animals

Endpoints

Flag link:

Landmark Study: Researchers Cure Lethal Disease in Prenatal Mice Using CRISPR

Landmark Study: Researchers Cure Lethal Disease in Prenatal Mice Using CRISPR

BioSpace

Flag link:

Skirting a group of pioneers, Gilead partners with gene-editing upstart Precision Bio in hunt to cure hep B

Skirting a group of pioneers, Gilead partners with gene-editing upstart Precision Bio in hunt to cure hep B

Endpoints

Gilead Sciences

Precision Biosciences

Flag link:

Allergan and Editas exercise CRISPR option

Allergan and Editas exercise CRISPR option

Biopharma Dive

Editas Medicine

Flag link:

Intellia Therapeutics, Inc. Stock History: The Story of a CRISPR Gene Editing Pioneer

Intellia Therapeutics, Inc. Stock History: The Story of a CRISPR Gene Editing Pioneer

Motley Fool

Intellia Therapeutics

Flag link:

Potential DNA damage from CRISPR has been ‘seriously underestimated,’ study finds

Potential DNA damage from CRISPR has been ‘seriously underestimated,’ study finds

Stat

Flag link:

CRISPR makes cancer cells turncoats that attack their tumor, mouse study finds

CRISPR makes cancer cells turncoats that attack their tumor, mouse study finds

Stat

Flag link:

How CRISPR tools are unlocking new ways to fight disease

How CRISPR tools are unlocking new ways to fight disease

Phys.org

Flag link:

A Deep Dive Into The Latest CRISPR Controversy: Here’s What You Should Know

A Deep Dive Into The Latest CRISPR Controversy: Here’s What You Should Know

Motley Fool

Flag link:

A serious new hurdle for CRISPR: Edited cells might cause cancer, find two studies

A serious new hurdle for CRISPR: Edited cells might cause cancer, find two studies

Stat

Flag link:

Gene Editing Pioneers Launch Beam Therapeutics With $87 Million Series A Round

Gene Editing Pioneers Launch Beam Therapeutics With $87 Million Series A Round

CP Wire

Beam Therapeutics

Flag link:

Gene editing shows promise in combating HIV reservoirs

Gene editing shows promise in combating HIV reservoirs

Fierce Biotech

Flag link:

CRISPR trials are about to begin in people—but we still don’t know how well it works in monkeys

CRISPR trials are about to begin in people—but we still don’t know how well it works in monkeys

MIT Technology Review

clinical trials

Flag link:

No Data Yet, But Homology Upsizes IPO and Raises $144M

No Data Yet, But Homology Upsizes IPO and Raises $144M

Xconomy

Flag link:

[video]Here’s Why Gilead Sciences' Jump Into Gene Editing Is Important

[video]Here’s Why Gilead Sciences' Jump Into Gene Editing Is Important

Motley Fool

Sangamo Therapeutics

Flag link:

Pages